As we aimed to use phenotypical drug screening to identify medicines for repurposing and assess potential mechanisms of action for TFE3 fusion tRCC, 45 chemotherapy agents with nonspecific cytotoxicity were excluded from the 101 compounds. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.